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Abstract: Chronic musculoskeletal pain is among the most frequent painful complaints that 
healthcare providers address. The bulk of these complaints are chronic low back pain and 
chronic osteoarthritis. Osteoarthritis is the most common form of arthritis in the United States. 
It is a chronic degenerative disorder characterized by a loss of cartilage, and occurs most often 
in older persons. The management of osteoarthritis and chronic low back pain may involve both 
nonpharmacologic (eg, weight loss, resistive and aerobic exercise, patient education, cognitive 
behavioral therapy) and pharmacologic approaches. Older adults with severe osteoarthritis 
pain are more likely to take analgesics than those with less severe pain. The pharmacologic 
approaches to painful osteoarthritis remain controversial, but may include topical as well as 
oral nonsteroidal antiinflammatory drugs, acetaminophen, duloxetine, and opioids. The role of 
duloxetine for musculoskeletal conditions is still evolving.
Keywords: pain, musculoskeletal, duloxetine, osteoarthritis, low back, serotonin-norepinephrine 
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Introduction
The majority of chronic musculoskeletal pain complaints are largely related to chronic 
low back pain and osteoarthritis. Chronic low back pain (CLBP) and osteoarthritis 
(OA) of any joint are highly prevalent occurring in .50% of United States adults 
aged .60 years. Opioids are prescribed more frequently for CLBP and OA than for any 
other noncancer pain, and the judicious use of opioids is recommended by treatment 
guidelines for the management of CLBP and OA pain.1
The number of patients who are prescribed opioids for chronic noncancer pain is 
increasing, representing more than one-third of all patients with chronic noncancer 
pain enrolled in a commercially insured national population.2,3 In this population, the 
most common etiologies of chronic noncancer pain for which patients received opioids 
were OA of proximal and peripheral joints and CLBP, which may also be caused by 
OA of the spine.2
OA and CLBP are among the most frequent causes of chronic noncancer pain 
and may be grouped together under chronic musculoskeletal disorders. OA and 
CLBP are often concurrent. Patients with OA of proximal and peripheral joints 
frequently have CLBP.4,5 Although OA and CLBP are both significantly associated 
with obesity, cardiovascular disease, and cardiovascular risk factors,6–9 the presence 
of OA in young adults predicts elevated risk of cardiovascular disease independent of 
obesity.10 The associations between chronic pain conditions, cardiovascular disease, 
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and cardiovascular risk factors may influence treatment 
decisions for the management of OA and CLBP.
Treatment guidelines for the management of CLBP11–13 
and OA pain14–16 all state that efforts to manage pain and 
improve function should be multimodal and begin with 
physical measures such as rehabilitation and exercise. 
Nonpharmacologic modalities include advice on effective 
self-care and maintenance of appropriate activity and exer-
cise; behavioral therapy and progressive relaxation; physi-
cal interventions, such as spinal manipulation (for CLBP), 
application of heat, use of orthotic devices (eg, back or 
knee braces), transcutaneous electrical nerve stimulation 
(for OA), and acupuncture; and multidisciplinary therapy 
or interdisciplinary rehabilitation.11,16 Nonpharmacologic 
treatments may be of particular importance in patients with 
CLBP for whom psychosocial factors such as depression, 
passive coping strategies, job dissatisfaction, greater dis-
ability, and somatization may be more predictive of poor 
outcome than pain intensity.11,17
When pharmacotherapy is required, acetaminophen 
is typically recommended as a first-line therapy for OA 
pain15,16 and CLBP.11 Acetaminophen is less effective than 
nonsteroidal antiinflammatory drugs (NSAIDs)8,18 and has 
shown the potential for hepatic toxicity at doses of .4 g/day.9 
In fact, the United States Food and Drug Administration is 
considering reducing the maximum dose to 3250 mg/day 
based on the clinical observation that the margin between 
the maximum recommended dose and a potentially toxic 
dose is lower than with other medications.19 The next step in 
pharmacotherapy is frequently an oral NSAID, which may 
provide adequate effectiveness for mild-to-moderate CLBP 
or OA pain.20,21 However, oral NSAIDs are associated with 
dose-related risks of gastrointestinal,22 cardiovascular,23 and 
renal24 adverse events (AEs). NSAIDs also have significant 
potential for interaction with drugs commonly prescribed to 
patients with heart disease, most notably antihypertensive 
drugs,25 warfarin,26 and low-dose cardioprotective aspirin.27 
Nonetheless, for patients with heightened risk of AEs with 
other treatments, a trial of nonselective NSAIDs with a proton 
pump inhibitor or celecoxib may be warranted.
Although several guidelines recommend oral NSAIDs as 
a first-line therapy in selected patients,11,16 American Geriatric 
Society guidelines for the management of persistent pain 
in older patients and the National Institute for Health and 
Clinical Excellence guidelines for OA suggest that NSAIDs 
should be avoided when possible.14,28
Both the National Institute for Health and Clinical 
Excellence guidelines and OA Research Society International 
guidelines for the management of hand and knee OA 
recommend topical NSAIDs over oral NSAIDs. Topical 
NSAIDs produce high drug concentrations in the treated joint 
with lower systemic NSAID exposure compared with oral 
NSAIDs29 and have demonstrated efficacy in patients with 
hand and knee OA pain.30–32 Topical NSAID trials have not 
been of sufficient length to conclusively gauge the long-term 
risk of serious AEs compared with oral NSAIDs; however, in 
12-week trials, topical formulations of diclofenac31–33 resulted 
in fewer gastrointestinal AEs, including bleeding events, and 
fewer discontinuations due to AEs than were reported with 
celecoxib, oral diclofenac, and naproxen in the SUCCESS 
(Successive Celecoxib Efficacy and Safety Studies) trial.34 
Topical NSAIDs are not indicated for and have not been 
studied for CLBP. Although only approved for the treatment 
of postherpetic neuralgia,35 the topical lidocaine 5% patch 
has shown efficacy in several trials of patients with OA of 
the knee36,37 and nonradicular CLBP,38–40 and may be consid-
ered to supplement other therapies as part of the multimodal 
approach to these painful conditions.
With adequate response to oral analgesics, intraarticular 
injections of hyaluronic acid or depocorticosteroids are 
recommended in current OA guidelines.15,16 In patients with 
CLBP, epidural or transforaminal corticosteroid injections 
are recommended for patients with suspected   radiculopathy.11 
In patients with severe or progressive OA, surgical replace-
ment has proven to be successful for the knee and hip 
joints,41,42 but not for the much smaller joints of the hand.43,44 
  Figure 1 is a biased nonconsensus algorithm for a topical/
oral pharmacologic approach to the treatment of painful OA 
before interventional approaches are used. This algorithm 
of the management of OA should not be viewed as a fixed 
and “concrete” treatment blueprint, but rather as a flexible 
dynamic guide to assist busy clinicians. Although duloxetine 
monotherapy is shown as a potential second-line pharma-
cologic agent, it is not meant to discourage clinicians from 
utilizing an NSAID first in any particular patient, but rather 
to suggest a loose framework in which to consider choosing 
various therapeutic agents. The authors chose to put dulox-
etine before NSAIDs or tramadol in the algorithm largely due 
to the potential adverse effects of NSAIDs (eg, peptic ulcer 
disease, gastrointestinal bleeding, renal insult) and tramadol 
(eg, seizures, opioid-like adverse effects such as the potential 
for tramadol misuse, abuse, addiction,45–49 or dose-related 
opioid physical dependency).50,51
The most recent OA Research Society International 
guidelines for the management of OA of the knee and hip 
recommend opioids for pain reduction, citing robust effect 
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size of 0.78 compared with 0.44 for topical NSAIDs, 0.29 for 
oral NSAIDs, and just 0.14 for acetaminophen.52 According 
to these guidelines, the most likely AEs with opioids include 
constipation, nausea, vomiting, dizziness, and somnolence, 
which are less serious than the potential AEs listed for oral 
NSAIDs (gastrointestinal perforations, ulcers, bleeding, 
and myocardial infarction).52 Guidelines from the American 
Pain Society in conjunction with the American Academy of 
Pain Medicine for the management of CLBP,11 and separate 
National Institute for Health and Clinical Excellence guide-
lines for the management of OA and CLBP,14,53 recommend 
long-term opioid therapy when anticipated benefits outweigh 
assessed risks for the management of severe pain that does 
not respond (or is unlikely to respond) to acetaminophen or 
NSAIDs or when NSAIDs are contraindicated. The European 
League Against Rheumatism guidelines for the management 
of hand OA state that the efficacy and safety of “weak   opioids” 
(opioids for mild to moderate pain), such as codeine or tra-
madol, need more study in randomized controlled trials,15 
whereas guidelines developed by the European Cooperation 
in Science and Technology B13 Working Group recommend 
both “weak and strong opioids” (opioids for mild to moderate 
pain [score of 5–10 on Numerical Rating Scale-11] and 
opioids for moderate to severe pain [score of 6–10 on 
Numerical Rating Scale-11]) for patients with CLBP, but 
state that further clinical data are needed to strengthen the 
recommendation for “strong opioids” (opioids for moderate 
to severe pain).54 The American Geriatric Society guidelines 
recommend opioids in selected older patients with persistent 
pain, observing that the risk of addiction is low in older 
patients without a history of abuse, whereas the risk of 
NSAID-related gastrointestinal, cardiovascular, and renal 
AEs increases with age.28
Pharmacologic overview  
of duloxetine
Duloxetine is classified pharmacologically as a serotonin-
norepinephrine reuptake inhibitor which possesses high 
Osteoarthritis
Nonpharmacologic measures
Topical
lidocaine
Topical
capsaicin
Oral APAP
(if no hepatic dx)
Topical NSAIDs
or salicylates
Oral glucosamine
and chondroitin sulfate
Oral
duloxetine
Oral antiinflammatory agents
(nonacetylated salicylates,
NSAIDs, COX-2 inhibitors)
with/without PPIs/misoprostol
Oral 
tramadol
“Traditional”
opioids
Tapentadol
1st line agents
2nd line agents
3rd line agents
4th line agents
Figure 1 Algorithm for topical/oral pharmacologic approach to the treatment of painful osteoarthritis.
Abbreviations: APAP, acetaminophen; dx, doxorubicin; NSAID, nonsteroidal antiinflammatory drug; PPI, proton pump inhibitor.
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inhibition constant, Ki, values for monoamine transporters 
(eg, serotonin and norepinephrine transporters).55 The 
inhibition constant, Ki, value reflects the potency of an 
inhibitor compound as the tightness affinity of binding to 
the monoamine transporter.55 Duloxetine inhibits serotonin 
reuptake significantly more than norepinephrine reuptake 
(in an approximate 10:1 ratio).56 Duloxetine is the (+)-(S) 
isomer of the racemic mixture with structural similarities to 
both fluoxetine and atomoxetine.55 It possesses a secondary 
amine structure unlike venlafaxine, the first approved 
serotonin-norepinephrine reuptake inhibitor, which pos-
sesses a tertiary amine structure.55 Duloxetine is approved 
by the Food and Drug Administration for the following 
uses: fibromyalgia, diabetic neuropathic pain, major depres-
sive disorder, generalized anxiety disorder,57 and chronic 
musculo  skeletal disorder.
Duloxetine is available in delayed-release enteric-coated 
capsules.55 The delayed-release formulation prevents dis-
solution in acidic conditions (pH , 5.5) such as those in 
the stomach, but allows for immediate release and rapid 
absorption at the pH in the small intestine.58 Duloxetine 
exhibits a peak effect on platelet serotonin reuptake at 
4–6 hours. Its inhibition persists for a duration of action 
of 7 days.55 The maximum plasma concentration 47 ng/mL 
(40 mg twice-daily dosing) is achieved 6 hours after a 
postprandial dose.59,60 The pharmacokinetics of duloxetine 
exhibit linearity and the steady-state concentration is 
reached in approximately 3–5 days.57 Its absorption and 
bioavailability are demonstrated to be 30%–80% (average 
about 50%).59,60 Duloxetine exhibits a high degree of protein 
binding (90%), and binds primarily to albumin and alpha-1 
acid glycoprotein.55
Duloxetine has a usual half-life of 8–17 hours.57 Its 
metabolic pathways include cytochrome P450 1A2 and 
2D6 (CYP1A2 and CYP2D6). In addition to being a 
substrate, duloxetine may produce mild inhibition of 
CYP1A2 and moderate inhibition of CYP2D6.58 CYP2D6 
exhibits genetic polymorphism and could potentially lead 
to the existence of poor, extensive, and ultraextensive 
metabolizers.55 Approximately 70% of duloxetine is 
renally excreted as metabolites, with ,1% as the parent 
compound.55 Metabolites found in plasma and urine include 
4-hydroxy duloxetine glucuronide (primarily) and 5-hydroxy 
or 6-hydroxy duloxetine further metabolized (to catechol 
duloxetine and then) to 5-hydroxy, 6-methoxy duloxetine 
sulfate (or glucuronide), neither of which appear to be 
significantly pharmacologically active.61 Thus, patients with 
renal impairment (creatinine clearance of 30–80 mL/minute) 
should receive an initial lower dosage (ie, 20 mg) with the 
dose increased gradually thereafter. Approximately 20% of 
duloxetine is excreted in the feces, possibly representing 
hepatobiliary secretion.55
Patient demographic characteristics found to influence 
the pharmacokinetics of duloxetine include sex, smoking 
status, age, ethnicity, CYP2D6 genotype, hepatic function 
and renal function. Of these, only impaired hepatic function 
or severely impaired renal function (creatinine clearance 
of ,30 mL/minute) warrant specific warnings or dose 
recommendations.58 The effect of sex and smoking status on 
duloxetine exposure is attributable to CYP1A2 metabolism 
since these factors may affect the expression and activity 
of CYP1A2.62,63 CYP1A2 activity in women is lower than 
in men and this decrement in CYP1A2 activity has an 
impact on the metabolism of duloxetine, resulting in higher 
duloxetine systemic concentration in women compared with 
men. Smoking increases the expression of CYP1A2, and 
this increased expression is associated with a 30% decrease 
in duloxetine concentration in smokers compared with 
nonsmokers. The combined effect of sex and smoking 
status typically results in duloxetine concentrations for a 
male smoker that are 57% lower than the concentrations in a 
female nonsmoker.58 In the presence of fluvoxamine, a potent 
CYP1A2 inhibitor, the oral bioavailability of duloxetine 
increased from 42.8% to 81.9%. Pharmacodynamic study 
results indicate that duloxetine may enhance the effects of 
benzodiazepines.58 Activated charcoal significantly decreased 
duloxetine maximum concentration by approximately 
32% and area under the curve by approximately 35%, 
likely resulting from the binding of duloxetine to the 
activated charcoal when duloxetine was released into the 
gastrointestinal content.58
Abrupt discontinuation of any serotonin-norepinephrine 
reuptake inhibitor, including duloxetine, can cause a multi-
tude of symptoms, including headache, dizziness, nightmares, 
irritability, paresthesia, and nausea/vomiting.55 Thus, it is rec-
ommended that this agent be decreased in small, decremental 
amounts over an extended period of time. There is also risk of 
serotonin syndrome (diaphoresis, hyperthermia, tachycardia, 
hyperreflexia) with this drug, especially if used in conjunc-
tion with other serotonin agents.57 In patients with a history 
of alcohol use, there is an increased risk of liver damage as 
preexisting hepatic damage may be present.55 In patients with 
controlled narrow-angle glaucoma, there may be an increased 
risk of mydriasis. Patients who are elderly or hypovolemic 
may develop hyponatremia with duloxetine. There have also 
been reports of the syndrome of inappropriate antidiuretic 
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hormone secretion in patients taking duloxetine or other 
serotonin-norepinephrine reuptake inhibitors. Finally, if use 
is initiated during pregnancy, it should be delayed until the 
third trimester (pregnancy category C).55 Adverse effects 
that may occur commonly (.10%) in patients include 
somnolence, dizziness, headaches, and insomnia.55 Possible 
cardiovascular effects include increase in blood pressure, 
orthostatic hypotension, syncope, and palpitations.57 Possible 
gastrointestinal effects include nausea, xerostomia, diarrhea, 
and constipation.55 Other adverse effects reported in patients 
include hyperhidrosis, sexual dysfunction, diminished 
appetite, and urinary hesitancy.55
Duloxetine for chronic 
musculoskeletal pain
Duloxetine may have potential advantages for patients with 
chronic musculoskeletal pain and comorbid depression, and/
or anxiety, simply because in this situation clinicians may 
be able to treat more than one condition with single-agent 
therapy. However, duloxetine can be used effectively as mono-
therapy for patients purely with chronic musculoskeletal pain 
without any accompanying depression or anxiety. Although 
the precise mechanisms by which duloxetine contributes to 
alleviation of chronic musculoskeletal pain remain uncertain, 
it is likely that duloxetine may enhance descending inhibi-
tory pain pathways by its actions of inhibiting the reuptake 
of serotonin and norepinephrine. It appears that there exist 
subgroups of patients with OA where central nervous system 
pain mechanisms (eg, loss of descending analgesic activity, 
central sensitization) may play a role in contributing to rest-
ing pain64,65 and movement-related pain.66
Quantitative sensory testing has revealed that OA patients 
have lower mechanical and thermal pain thresholds than 
healthy controls at sites close to affected joints,66–69 as well 
as at distant sites.70,71
Bajaj et al infused hypertonic saline into the tibialis 
anterior muscles of 14 OA patients and 14 age-matched and 
sex-matched controls.72 The OA patients reported muscle 
pain that was of increased intensity, covered larger pain areas 
(extending to the toes), and persisted for a longer duration 
than controls.72 Bajaj et al suggested that this was due to 
central pain mechanisms in the OA patients.72 Kosek and 
Ordeberg demonstrated that the loss of descending analgesic 
activity found in patients with hip OA was restored after hip 
surgery in most patients who reported significant clinical 
pain relief.71
In a study of 48 knee OA patients and 24 age-matched 
and sex-matched controls, OA patients exhibited central 
sensitization as well as greater loss of descending analgesic 
activity than healthy controls.68 The investigators measured 
(1) pressure pain thresholds; (2) spreading sensitization; 
(3) temporal summation to repeated pressure pain stimu-
lation; (4) pain responses after intramuscular hypertonic 
saline; and (5) pressure pain modulation by heterotopic 
descending noxious inhibitory control (now referred to as 
conditioned pain modulation).68 The patients were separated 
into strong/severe (Visual Analog Scale $6) and mild/
moderate pain (Visual Analog Scale ,6) groups. Pressure 
pain thresholds were measured from the peripatellar region, 
tibialis anterior, and extensor carpi radialis longus muscles 
before, during, and after descending noxious inhibitory 
control. Temporal summation to pressure was measured 
at the most painful site in the peripatellar region and over 
tibialis anterior. Patients with severely painful OA pain had 
significantly lower pressure pain threshold than controls. 
Significantly negative correlations between Visual Analog 
Scale and pressure pain threshold were found (eg, more 
pain, more sensitization) for all sites (eg, knee, leg, arm). 
OA patients showed a significant facilitation of temporal 
summation from both the knee and tibialis anterior, and had 
significantly less descending noxious inhibitory control as 
compared with controls.68
Efficacy and safety of duloxetine
Three major 12-week double-blind, placebo-controlled 
studies were conducted as part of efforts to demonstrate the 
safety and efficacy of duloxetine for patients with CLBP. The 
first two trials included flexible doses from 60 mg to 120 mg 
once daily,73,74 whereas the third study focused on fixed dose 
duloxetine (60 mg once daily).75
Although 404 patients were enrolled, only 267 patients 
completed the study. No significant differences existed 
between any dose of duloxetine and placebo on reduc-
tion in weekly mean 24-hour average pain at endpoint. 
Duloxetine 60 mg was superior to placebo from week 
three to week eleven in relieving pain, but not at week 
twelve and week 13. Duloxetine 60 mg demonstrated 
significant improvement on Patient Global Impression of 
Improvement, Roland–Morris Disability Questionnaire-24, 
Brief Pain Inventory (BPI) average pain and BPI average 
interference. Significantly more patients taking duloxetine 
120 mg (24.1%) discontinued because of AEs compared 
to placebo (8.5%).73
In the first study, Skljarevski et al conducted a 13-week 
multicenter, randomized, double-blind, parallel, placebo-
controlled trial that assessed the efficacy of duloxetine 20, 
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60, and 120 mg once daily compared with placebo on the 
reduction of pain in patients with CLBP.73 In a second study, 
Skljarevski et al conducted a randomized double-blind trial 
that treated adult nondepressed patients who had nonneu-
ropathic CLBP and a weekly mean 24-hour average pain 
score of $4 at baseline (0–10 scale) with either duloxetine 
or placebo for 13 weeks. The dose of duloxetine during 
the first 7 weeks was 60–120 mg once daily. Compared 
with placebo-treated patients (least-squares mean change 
of −1.50), patients on duloxetine (least-squares mean change 
of −2.32) had a significantly greater reduction in the BPI 
24-hour average pain score from baseline to endpoint 
(P = 0.004 at week 13). Additionally, the duloxetine group 
significantly improved on Patient Global Impression of 
Improvement, Roland–Morris Disability Questionnaire-24, 
BPI pain severity, and BPI average interference weekly 
mean 24-hour average pain score, night pain, and worst 
pain. Significantly more patients in the duloxetine group 
(13.9%), compared with placebo (5.8%), discontinued 
because of AEs (P = 0.047). The most common treatment-
emergent AEs in the duloxetine group included nausea, 
dry mouth, fatigue, diarrhea, hyperhidrosis, dizziness, and 
constipation.74
In a third study, Skljarevski et al conducted a randomized, 
double-blind, placebo-controlled study that assessed efficacy 
and safety of duloxetine in patients with CLBP. Adults 
(N = 401) with nonneuropathic CLBP and an average pain 
intensity of 24 on an eleven-point numerical scale (BPI) were 
treated with either duloxetine 60 mg once daily or placebo 
for 12 weeks.75
Of the total patients randomized to placebo (N = 203) 
or duloxetine (N = 198), 76.8% and 74.2% of patients, 
respectively, completed the study. There was no statisti-
cally significant difference in overall discontinuation rates. 
Significantly (P = 0.02) more patients discontinued because 
of a lack of efficacy in the placebo treatment group (4.4%) 
compared with the duloxetine group (0.5%). In addition, 
significantly (P = 0.002) more patients discontinued because 
of AEs in the duloxetine treatment group (15.2%) compared 
with the placebo group (5.4%).75
Compared with placebo-treated patients, duloxetine-
treated patients reported a significantly greater reduction 
in BPI average pain (P = 0.001). Similarly, duloxetine-
treated patients reported significantly greater improvements 
in Patient Global Impression of Improvement, BPI pain 
severity, BPI average interference, 50% response rates, 
and some health outcomes. The Roland–Morris Disability 
Questionnaire-24 and 30% response rate showed numerical   
improvements with duloxetine treatment. Significantly 
more patients in the duloxetine group (15.2%), compared 
to the placebo group (5.4%), discontinued because of AEs 
(P = 0.002). Nausea and dry mouth were the most common 
treatment-emergent AEs with rates significantly higher in 
duloxetine-treated patients.75
Karp et al conducted an open-label duloxetine and 
care management therapy in the overall management of 
older adults with comorbid major depressive disorder 
and CLBP.76 Most (93.3%, n = 28) had a significant pain 
response. The mean time to depression remission was 
7.6 (standard error = 0.6) weeks. The mean time to pain 
response was 2.8 (standard error = 0.5) weeks. There were 
significant improvements in mental health-related quality 
of life, anxiety, sleep quality, somatic complaints, and both 
self-efficacy for pain management and for coping with 
symptoms.76
Two pivotal studies were conducted as a regulatory 
requirement to assess the efficacy and safety of duloxetine 
in patients with chronic pain due to OA of the knee.77,78 
Chappell et al conducted a 13-week randomized, placebo-
controlled trial of duloxetine (60–120 mg/day) in 174 patients 
(74.9% of the total 231 who enrolled) with significant knee 
pain from OA.77 Duloxetine was superior to placebo on the 
primary efficacy measure (weekly mean 24-hour average 
pain scores) beginning at week one and continuing through 
the treatment period (P # 0.05). There was also a significant 
improvement in the Western Ontario and McMaster 
University OA Index (WOMAC) physical functioning 
subscale and several other secondary outcomes.77 Path 
analysis demonstrated that 95% of the effect was due to 
analgesic efficacy rather than any reduction in symptoms of 
depression or anxiety. When dose differences were measured 
from baseline to end point, the 120-mg dose was statistically 
better than the 60-mg dose, but when response rates defined 
by a 30% and 50% reduction in pain were used, no dose 
differential was found. There was no difference in dropout 
rate between placebo and duloxetine groups. There was no 
difference in serious AEs between the duloxetine (49.5%) 
and placebo (40.8%) groups.77
Chappell et al conducted another 13-week randomized, 
double-blind, placebo-controlled trial in 204 patients (of the 
total 206 patients enrolled) meeting the American College of 
Rheumatology clinical and radiographic criteria for OA of 
the knee.78 Patients treated with duloxetine had significantly 
(P # 0.001) greater improvement at all time points on BPI 
average pain and had significantly greater improvement 
on BPI pain severity ratings (P # 0.05), WOMAC total 
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(P = 0.044) and physical functioning scores (P = 0.016), 
and Clinical Global Impressions-Severity (P = 0.009) at the 
study endpoint. Frequency of treatment-emergent nausea, 
constipation, and hyperhidrosis were significantly higher 
in the duloxetine group (P # 0.05). Significantly more 
duloxetine-treated patients discontinued the trial because of 
AEs (P = 0.002).78 Treatment with duloxetine 60–120 mg 
once daily was associated with significant pain reduction 
and improved function in patients with pain due to OA of 
the knee.78
Hochberg et al pooled data from two 13-week 
randomized, double-blind, placebo-controlled trials77,78 
comparing duloxetine 60–120 mg/day with placebo in 
patients with symptomatic OA of the knee.79 Treatment 
response was determined according to the Outcome 
Measures in Rheumatoid Arthritis Clinical Trials-OA 
Research Society International responder index, $30% 
pain reduction, $50% pain reduction, and minimal 
clinically important improvement and patient acceptable 
symptom state for pain and function. Duloxetine-treated 
patients were 33% more likely to experience a response 
than placebo-treated patients (P , 0.001, number needed 
to treat [NNT] = 6). A significantly greater percentage 
of duloxetine-treated patients, compared with placebo-
treated patients, reported $30% improvement in pain from 
baseline to endpoint (P , 0.001, NNT = 5) and $50% 
improvement in pain relative to baseline (P , 0.001, 
NNT = 7). The duloxetine-treated patients were also more 
likely to fulfill minimal clinically important improvement 
criteria for pain (P , 0.001, NNT = 6) and function 
(P , 0.001, NNT = 7), and to achieve patient acceptable 
symptom state for pain (P , 0.001, NNT = 6) and function 
(P = 0.009, NNT = 9). More duloxetine-treated patients 
compared with placebo-treated patients experienced at least 
one treatment-emergent AE (P = 0.003, number needed to 
harm = 8).79
Sullivan et al performed a single-blind, placebo run-in 
trial of 60–90 mg duloxetine in 25 subjects with activity-
limiting OA pain. Each subject received 2 weeks of placebo 
followed by 10 weeks of duloxetine. The primary outcome 
was reduction in average pain intensity between 2–12 weeks 
for subjects completing the trial.80 Average pain on the BPI 
was 5.7 at baseline, 4.8 after the 2-week placebo run-in, 
and 3.5 at 12 weeks for the 17 patients completing the trial 
(28% decrease between 2 weeks and 12 weeks, P = 0.122). 
Eight of the 15 study completers who had nonmissing BPI 
results (53%) reported at least 30% pain reduction between 
2 weeks and 12 weeks. The WOMAC pain score at baseline 
was 2.3, 1.8 after 2 weeks, and 1.3 after 12 weeks (30% 
decrease between 2 weeks and 12 weeks, P = 0.018). Ten of 
17 patients (59%) reported at least 30% pain relief between 
2 weeks and 12 weeks on the WOMAC.64 Duloxetine did 
not significantly reduce pain intensity on the BPI, but did 
improve pain intensity and self-reported function on the 
WOMAC.80
Therapy with duloxetine has also been reported for other 
chronic musculoskeletal conditions. Two mentally healthy 
young Asian women aged 32 and 27 years, each with tennis 
elbow of about 18 months duration, continued to suffer pain 
despite treatment with analgesics, local steroid injections, 
physiotherapy, cryotherapy, ultrasound, and surgical 
release, among other interventions. Both showed substantial 
improvement within 4–6 weeks of receiving monotherapy 
with duloxetine 60 mg/day. Both were pain-free with con-
tinued treatment at a 6-month follow-up.81
Brunton et al analyzed data from all placebo-controlled 
trials of duloxetine completed as of December 2008 for 
adverse effects. The 52 studies included 17,822 patients 
(duloxetine, N = 10,326; placebo, N = 7496) with major 
depressive disorder, generalized anxiety disorder, diabetic 
peripheral neuropathic pain, fibromyalgia, OA knee pain, 
CLBP, and lower urinary tract disorders.82 The overall 
treatment-emergent AE rate was 57.2% for placebo-
treated patients and 72.4% for duloxetine-treated patients 
(P # 0.001). Patients with OA knee pain had the lowest 
treatment-emergent AE rate (placebo 36.7% versus dulox-
etine 50.2%, P # 0.01), while patients with fibromyalgia had 
the highest rate (placebo 80.0% versus duloxetine 89.0%, 
P # 0.001). The most common treatment-emergent AE for 
all indications was nausea (placebo 7.2% versus duloxetine 
23.4%, P # 0.001), which was predominantly mild to 
moderate in severity.82
As far as AEs for the treatment of musculoskeletal pain 
in placebo-controlled clinical trials, the overall discontinu-
ation rates due to AEs were 16.3% versus 5.6% for OA and 
16.5% versus 6.3% for CLBP (Table 1). The common AEs 
reported as a reason for discontinuation and considered to be 
drug related were nausea (2.9% versus 0.8%) and asthenia 
(1.3% versus 0%) for OA and nausea (3.0% versus 0.7%) 
and somnolence (1.0% versus 0%) for CLBP.
Frakes et al conducted a 10-week randomized, double-
blind, placebo controlled trial in efforts to determine the 
efficacy, tolerability, and safety of duloxetine when added 
to oral NSAIDs in patients with OA of the knee with pain 
of moderate or greater severity (score of 4–6 on Numerical 
Rating Scale-11).84 It was a flexible-dose (duloxetine 
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60/120 mg/day), placebo-controlled trial that enrolled 
adult outpatients who had persistent moderate or greater 
pain ($4 on Numerical Rating Scale-11) due to OA of 
the knee despite, per protocol, having received optimized 
oral NSAID therapy (specific drug, dose, and frequency at 
investigator discretion). A total of 524 patients randomly 
received duloxetine 60/120 mg/day (N  =  264) or placebo 
(N  =  260). In total, 74% of the patients completed the 
study.83 Duloxetine-treated patients had significantly greater 
pain reduction at week eight (P , 0.001) than placebo-
treated patients. In addition, relative to placebo at week eight, 
duloxetine-treated patients had significant improvements in 
physical function as measured by the WOMAC (P  ,  0.001) 
and Patient Global Impression of Improvement (P  ,  0.001). 
Compared to placebo, significantly more nausea, dry mouth, 
constipation, fatigue, and decreased appetite were reported 
by patients taking duloxetine (each P  ,  0.05).84 Frakes et al 
concluded that duloxetine added to oral NSAID therapy 
provided additional significant pain reduction, improved 
function, and patient-rated impression of improvement. 
AEs were consistent with those seen in previous duloxetine 
trials. The short duration of the study may not reflect 
the long-term efficacy and safety of NSAID/duloxetine   
cotherapy.84
Summary
Musculoskeletal pain remains one of the most common pain 
complaints brought to health care providers. The manage  ment 
of various musculoskeletal conditions is extremely complex, 
controversial, and involves nonpharmacologic, pharmacologic 
and interventional approaches. Pharmacologic approaches 
may include acetaminophen, NSAIDs, muscle relaxants, 
topical NSAIDs, topical lidocaine, topical capsaicin, opioids/
dual mechanism agents (tramadol, tapentadol) and duloxetine. 
Duloxetine is a serotonin-norepinephrine reuptake inhibitor 
that has been shown to be safe and efficacious for painful 
musculoskeletal conditions. In the three trials of duloxetine 
for low back pain, the rate of discontinuation of duloxetine 
as a result of side effects compared with placebo was: 
24.1% versus 8.5%;73 13.9% versus 5.8%74 – and 15.2% 
versus 5.4%.75 The most common treatment-emergent AEs 
were nausea fatigue, diarrhea, hyperhidrosis, dizziness, 
constipation, and dry mouth.73,74,75 In the OA trials, the rate 
of discontinuation of duloxetine as a result of side effects 
compared with placebo was: 13.5% versus 5.8%77 and 
18.8% versus 5.4%75 (P = 0.002)75 The role of duloxetine 
for musculoskeletal conditions is evolving. Although there 
are no studies that would currently support that duloxetine 
is particularly well suited for any specific subgroups of 
patients with OA, the authors propose that duloxetine be 
studied in subgroups of OA patients with joints without overt 
signs of inflammation and especially in more “proximally 
located joints” (eg, knees, hips, shoulders, elbows, sacroiliac 
joints). They also propose that a subset of patients with OA 
who use pain quality descriptors suggestive of neuropathic 
pain (eg, heat, pins and needles, tingling) to describe their 
discomfort85 may be particularly well suited to respond to 
duloxetine therapy. Furthermore, it may even be conceivable in 
the future that the analgesic response to certain interventions 
(eg, transcutaneous electrical nerve stimulation)86 may help 
“tease out”/identify specific subpopulations of patients 
with chronic musculoskeletal pain (eg, OA) that may 
respond particularly well to duloxetine. Also, patients with 
inefficient conditional pain modulation may respond better to   
duloxetine.87 Furthermore, it remains to be seen if duloxetine 
combined with another analgesic agent may be useful for 
patients with painful musculoskeletal conditions who do not 
respond satisfactorily to monotherapy.
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Table 1 Duloxetine adverse events for treatment of musculo-
skeletal pain
Chronic low  
back pain
Duloxetine 
20/60/120 mg/day  
(N = 600)
Placebo  
(N = 441)
Nausea 16.2% 2.9%
Dry mouth 
Insomnia 
Somnolence 
Constipation 
Dizziness 
Fatigue
8.5% 
8.0% 
7.7% 
7.3% 
6.3% 
6.3%
2.0% 
3.6% 
1.4% 
2.0% 
1.8% 
0.9%
Osteoarthritis Duloxetine 
60/120 mg/day  
(N = 239)
Placebo 
(N = 248)
Nausea 
Fatigue 
Constipation
8.4% 
6.7% 
5.9%
2.0% 
0.8% 
0.8%
Notes: Most common adverse events reported at a rate of $5% with duloxetine 
and at least twice the rate of placebo. Cymbalta®.83
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